Latest news with #InspireMedicalSystems
Yahoo
3 days ago
- Business
- Yahoo
Inspire Medical Systems, Inc. to Participate in the Wells Fargo 2025 MedTech Innovation Spotlight
MINNEAPOLIS, May 30, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will participate in the Wells Fargo 2025 MedTech Innovation Spotlight on Friday, June 13, 2025. Inspire is scheduled to present at 12:00 p.m. Eastern Time. The presentation will be accessible via a live webcast here. A webcast replay of the presentation will be available for two weeks following the presentation in the Event Archive section of Inspire's Investor website at About Inspire Medical SystemsInspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire's proprietary Inspire therapy is the first and only FDA, EU MDR, and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. For additional information about Inspire, please visit Investor and Media ContactEzgi YagciVice President, Investor Relationsezgiyagci@ in to access your portfolio
Yahoo
12-05-2025
- Business
- Yahoo
3 Healthcare Stocks to Keep an Eye On
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand. The result? Over the past six months, the industry has tumbled by 13%. This drop was worse than the S&P 500's 5.5% loss. Only some companies are subject to these dynamics, however, and a handful of high-quality businesses can deliver earnings growth in any environment. Taking that into account, here are three healthcare stocks boasting durable advantages. Market Cap: $145.6 billion With over 150 million patients impacted annually through its innovative healthcare technologies, Stryker (NYSE:SYK) develops and manufactures advanced medical devices and equipment across orthopedics, surgical tools, neurotechnology, and patient care solutions. Why Is SYK Interesting? Existing business lines can expand without risky acquisitions as its organic revenue growth averaged 10.4% over the past two years Economies of scale give it some operating leverage when demand rises Solid free cash flow generation relative to most peers gives it a cushion and grants it various reinvestment opportunities At $380.96 per share, Stryker trades at 27.6x forward P/E. Is now the right time to buy? See for yourself in our in-depth research report, it's free. Market Cap: $4.46 billion Offering an alternative for the millions who struggle with traditional CPAP machines, Inspire Medical Systems (NYSE:INSP) develops and sells an implantable neurostimulation device that treats obstructive sleep apnea by stimulating nerves to keep airways open during sleep. Why Are We Bullish on INSP? Measured rollout of new domestic medical centers communicates a gradual expansion strategy Earnings per share grew by 26.7% annually over the last five years, massively outpacing its peers Free cash flow margin jumped by 48.2 percentage points over the last five years, giving the company more resources to pursue growth initiatives, repurchase shares, or pay dividends Inspire Medical Systems is trading at $151.25 per share, or 55.1x forward P/E. Is now the time to initiate a position? Find out in our full research report, it's free. Market Cap: $659.4 billion Founded in 1876 by a Civil War veteran and pharmacist who was frustrated with the poor quality of medicines available at the time, Eli Lilly (NYSE:LLY) discovers, develops, and manufactures pharmaceutical products for conditions including diabetes, obesity, cancer, immunological disorders, and neurological diseases. Why Will LLY Beat the Market? Impressive 33% annual revenue growth over the last two years indicates it's winning market share this cycle Share repurchases have amplified shareholder returns as its annual earnings per share growth of 17.6% exceeded its revenue gains over the last five years Market-beating returns on capital illustrate that management has a knack for investing in profitable ventures Eli Lilly's stock price of $736.58 implies a valuation ratio of 28.9x forward P/E. Is now a good time to buy? See for yourself in our comprehensive research report, it's free. Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today for free. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
07-05-2025
- Business
- Yahoo
Haemonetics (HAE) To Report Earnings Tomorrow: Here Is What To Expect
Blood products company Haemonetics (NYSE:HAE). will be reporting results tomorrow before market open. Here's what you need to know. Haemonetics missed analysts' revenue expectations by 1.3% last quarter, reporting revenues of $348.5 million, up 3.7% year on year. It was a slower quarter for the company, with organic revenue in line with analysts' estimates. Is Haemonetics a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Haemonetics's revenue to decline 4.7% year on year to $327.3 million, a reversal from the 12.8% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.22 per share. Haemonetics Total Revenue Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Haemonetics has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 2.7% on average. Looking at Haemonetics's peers in the medical devices & supplies - specialty segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Inspire Medical Systems delivered year-on-year revenue growth of 22.7%, beating analysts' expectations by 3.1%, and Integer Holdings reported revenues up 7.3%, topping estimates by 2%. Inspire Medical Systems traded up 1.8% following the results while Integer Holdings was also up 2.6%. Read our full analysis of Inspire Medical Systems's results here and Integer Holdings's results here. There has been positive sentiment among investors in the medical devices & supplies - specialty segment, with share prices up 5.9% on average over the last month. Haemonetics is up 13.5% during the same time and is heading into earnings with an average analyst price target of $96.30 (compared to the current share price of $63.58). When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we've found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.
Yahoo
07-05-2025
- Business
- Yahoo
Earnings To Watch: Globus Medical (GMED) Reports Q1 Results Tomorrow
Medical device company Globus Medical (NYSE:GMED) will be announcing earnings results tomorrow after market close. Here's what to look for. Globus Medical beat analysts' revenue expectations by 1.9% last quarter, reporting revenues of $657.3 million, up 6.6% year on year. It was a strong quarter for the company, with an impressive beat of analysts' EPS estimates and a narrow beat of analysts' constant currency revenue estimates. Is Globus Medical a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Globus Medical's revenue to grow 3.4% year on year to $627.6 million, slowing from the 119% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.74 per share. Globus Medical Total Revenue Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Globus Medical has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 0.5% on average. Looking at Globus Medical's peers in the medical devices & supplies - specialty segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Inspire Medical Systems delivered year-on-year revenue growth of 22.7%, beating analysts' expectations by 3.1%, and Integer Holdings reported revenues up 7.3%, topping estimates by 2%. Inspire Medical Systems traded up 1.8% following the results while Integer Holdings was also up 2.6%. Read our full analysis of Inspire Medical Systems's results here and Integer Holdings's results here. There has been positive sentiment among investors in the medical devices & supplies - specialty segment, with share prices up 5.9% on average over the last month. Globus Medical is up 2.6% during the same time and is heading into earnings with an average analyst price target of $97.46 (compared to the current share price of $70.43). When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we've found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.
Yahoo
05-05-2025
- Business
- Yahoo
Inspire Medical Systems's (NYSE:INSP) Q1: Strong Sales, Stock Soars
Medical technology company Inspire Medical Systems (NYSE:INSP) announced better-than-expected revenue in Q1 CY2025, with sales up 22.7% year on year to $201.3 million. The company expects the full year's revenue to be around $947.5 million, close to analysts' estimates. Its GAAP profit of $0.10 per share was significantly above analysts' consensus estimates. Is now the time to buy Inspire Medical Systems? Find out in our full research report. Revenue: $201.3 million vs analyst estimates of $195.2 million (22.7% year-on-year growth, 3.1% beat) EPS (GAAP): $0.10 vs analyst estimates of -$0.24 (beat) Adjusted EBITDA: $33.19 million vs analyst estimates of $16.51 million (16.5% margin, significant beat) The company reconfirmed its revenue guidance for the full year of $947.5 million at the midpoint EPS (GAAP) guidance for the full year is $2.25 at the midpoint, beating analyst estimates by 4.1% Operating Margin: -0.7%, up from -9.3% in the same quarter last year Market Capitalization: $4.76 billion 'We are very proud of our performance in the first quarter which included strong revenue growth and continued progress on profitability. We achieved a tremendous milestone with over 100,000 patients receiving Inspire therapy and we are still just getting started in growing awareness and adoption,' said Tim Herbert, Chairman and CEO of Inspire Medical Systems. Offering an alternative for the millions who struggle with traditional CPAP machines, Inspire Medical Systems (NYSE:INSP) develops and sells an implantable neurostimulation device that treats obstructive sleep apnea by stimulating nerves to keep airways open during sleep. Reviewing a company's long-term sales performance reveals insights into its quality. Any business can have short-term success, but a top-tier one grows for years. Over the last five years, Inspire Medical Systems grew its sales at an incredible 57.3% compounded annual growth rate. Its growth surpassed the average healthcare company and shows its offerings resonate with customers, a great starting point for our analysis. Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. Inspire Medical Systems's annualized revenue growth of 34.2% over the last two years is below its five-year trend, but we still think the results suggest healthy demand. This quarter, Inspire Medical Systems reported robust year-on-year revenue growth of 22.7%, and its $201.3 million of revenue topped Wall Street estimates by 3.1%. Looking ahead, sell-side analysts expect revenue to grow 18.2% over the next 12 months, a deceleration versus the last two years. Still, this projection is admirable and implies the market is forecasting success for its products and services. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Although Inspire Medical Systems broke even this quarter from an operational perspective, it's generally struggled over a longer time period. Its expensive cost structure has contributed to an average operating margin of negative 5.6% over the last five years. Unprofitable healthcare companies require extra attention because they could get caught swimming naked when the tide goes out. On the plus side, Inspire Medical Systems's operating margin rose by 47.2 percentage points over the last five years, as its sales growth gave it operating leverage. Zooming in on its more recent performance, we can see the company's trajectory is intact as its margin has also increased by 16.9 percentage points on a two-year basis. These data points are very encouraging and shows momentum is on its side. In Q1, Inspire Medical Systems generated a negative 0.7% operating margin. Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions. Inspire Medical Systems's full-year EPS flipped from negative to positive over the last five years. This is a good sign and shows it's at an inflection point. In Q1, Inspire Medical Systems reported EPS at $0.10, up from negative $0.34 in the same quarter last year. This print easily cleared analysts' estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects Inspire Medical Systems's full-year EPS of $2.17 to grow 26.7%. We liked that Inspire Medical Systems beat across the board, exceeding analysts' revenue, adjusted EBITDA, and EPS expectations this quarter. Its full-year EPS guidance outperformed Wall Street's estimates, as the company maintained its outlook from the previously-provided one. Zooming out, we think this quarter featured some important positives. The stock traded up 6.8% to $170 immediately after reporting. Indeed, Inspire Medical Systems had a rock-solid quarterly earnings result, but is this stock a good investment here? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free.
